Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDY08K)

Drug Name

GDC-0623 Drug Info

Synonyms

1168091-68-6; GDC 0623; UNII-HW67545I4Q; RG 7421; GDC0623; HW67545I4Q; G-868; Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-; 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE; RFWVETIZUQEJEF-UHFFFAOYSA-N; GTPL9909; SCHEMBL1615104; CHEMBL3330650; MolPort-039-193-834; BCP28689; AOB87143; EX-A2060; s7553; ZINC43206499; BDBM50025226; AKOS027253679; DB11982; SB16957; CS-2281; BC600628; HY-15610; KB-144448; FT-0769207; Z-3311

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 42642654
CAS Number: CAS 1168091-68-6
TTD Drug ID: DMDY08K

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting ERK activator kinase (MEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-162	DM1P6FR	Melanoma	2C30	Approved	[2]
NFX-179	DM77XQT	Neurofibromatosis 1	LD2D.10	Phase 2	[3]
HL-085	DMJDVCW	Melanoma	2C30	Phase 1/2	[4]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
BI 3011441	DMFJGUL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Pyridinone compound 1	DM2GR5Q	N. A.	N. A.	Patented	[7]
Quinazolines and azaquinazoline derivative 1	DME24BI	N. A.	N. A.	Patented	[7]
PMID28594589-Compound-TABLE3C2	DMVYG0U	N. A.	N. A.	Patented	[7]
Benzoheterocyclic compound 1	DM3K25J	N. A.	N. A.	Patented	[7]
Benzoimidazole derivative 1	DMUJFCK	N. A.	N. A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ERK activator kinase (MEK)	TTZCRP3	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Genentech (2011).
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	Clinical pipeline report, company report or official report of NFlection Therapeutics
4	Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
5	Clinical pipeline report, company report or official report of Roche.
6	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
7	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.